Synthon Biopharmaceuticals Reports Positive Early Results With Its Second Generation

[News]

Best-in-Class potential with improved therapeutic index compared to other armed antibodies Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs)...

More... (http://www.medicalnewstoday.com/releases/255298.php)